Fig. 7
Histological analyses for assessing response to bevacizumab treatment. A Immunofluorescence staining of tumor vasculature and integrin β3 with antibodies against CD31 (green) and CD61 (integrin β3, red) in the treated and control groups at the end of the study. B Quantitative analysis of integrin β3 and CD31-positive area fraction of tumors between the control and treatment groups. **P < 0.05. Magnification: ×200. Microvascular density (CD31) from the therapy group (C) and control group (D). Tumor cell proliferation (Ki-67) from the therapy group (F) and control group (G). Quantitative MVD (E) and Ki67 (H) assessment of therapy and control group. Error bars denote standard errors, Mann–Whitney U-test were applied, **P < 0.05. Magnification: ×200